• It’s today’s top story: Arena Pharmaceuticals’ lorcaserin met some of its endpoints in a pivotal trial for obesity, but the study did not meet the placebo-adjusted weight loss difference of 5%. Stock down 28%. Just another example of how hard it is to get an obesity drug approved and how the FDA WILL NEVER approve one. [WSJ Health Blog]

• Tomorrow’s a big day for Avastin; oncology panel will weigh benefits in brain cancer. [FiercePharma]

• J&J is throwing a monkeywrench into the Merck/Schering-Plough deal, wants cut. [Financial Times]

• Pfizer beat Abbott for Wyeth – what will Abbott do now? [WSJ Deal Journal]

ACC Roundup

• Schering-Plough’s Integrilin doesn’t produce better results when administered early in surgery. [Bloomberg]

• Intensive Lipitor Therapy Provided Sustained Risk Reduction Of Cardiovascular Events In Older Patients With Heart Disease. [Pharmalive]

• Crestor reduces the risk of DVTs by 43%. [The Motley Fool]

• Arca Biopharma’s bucindolol best Phase 3 trial at ACC. [RTTNews]

Image from independent

Related Posts